The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win

기사 요약

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.